摘要
药物基因组学是在药物遗传学基础上发展起来的新兴学科，是分子药理学与功能基因组学结合的产物。通过研究药物代谢、转运及药物作用受体相关基因单核苷酸多态性（SNP）对药物疗效的影响，开发新药、指导临床合理用药，从而提高药物的疗效及安全性^[1]。候选基因主要包括药物代谢酶、药物转运蛋白以及药物受体基因。近年来对临床用药药物基因组学的研究日益增多，但有关糖尿病用药的研究尚少。随着糖尿病患病率的逐年升高，人们对糖尿病合理用药更加关注，这就促进了降糖药药物基因组学的发展。
出处
《上海医学》
CAS
CSCD
北大核心
2008年第5期370-373,共4页
Shanghai Medical Journal
参考文献25
-
1Evans W E, Relling M V. Pharmacogenomics; translating functional genomics into rational therapeutics. Science, 1999,286: 487-491.
-
2Goldberg R B, Einhorn D, Lucas C P, et al. A randomized placebo-controlled trial of repaglinlde in the treatment of type 2 diabetes. Diabetes Care, 1998, 21:1897-1903.
-
3Niemi M, Leathart J B, Neuvonen M,et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther, 2003,74 : 380 -387.
-
4Kirchheiner J, Meineke I, Muller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokine tics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet, 2004,43:267- 278.
-
5Dai D, Zeldin D C, Blaisdell J A,et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 2001, 11:597-607.
-
6Bidstrup T B, Bjφrnsdottir I, Sidelmann U G,et al. CYP2C8and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repag linide.Br J Clin Pharmacol, 2003,56 : 305-314.
-
7McLeod J F. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharma cokinet, 2004,43: 97-120.
-
8Klose T S, Blaisdell J A, Goldstein J A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol, 1999,13:289-295.
-
9Niemi M, Backman J T, Neuvonen M,et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46: 347-351.
-
10Bahadur N, Leathart J B, Mutch E,et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biothem Pharmacol, 2002,64:1579-1589.
同被引文献26
-
1赵明,杜宏,王燕燕,王坚.磺脲类药物受体基因多态性和2型糖尿病、磺脲类药物疗效相关性初步研究[J].中华内科杂志,2003,42(11):808-809. 被引量：4
-
2张伟,王安,周宏灏.口服降糖药的遗传药理学研究进展[J].中国临床药理学与治疗学,2007,12(1):7-10. 被引量：5
-
3杨毅,郭丽敏,杨金奎.SUR1 Ser1369Ala多态性与磺脲类药物疗效的相关性[J].基础医学与临床,2007,27(5):521-524. 被引量：3
-
4陈莉丽,李强,邢厚恂,任晓炜,孙玉倩,刘枫晨,梁梅花,张众,张巾超.磺脲类受体1基因多态性对磺脲类降糖药物作用的影响[J].第二军医大学学报,2007,28(7):765-767. 被引量：4
-
5Nora N,Ana-Maria S,Darko K,et al.Metabolic control in type 2 diabetes is associated with sulfonyluren receptor-l (SUR-1) but not with KCNJI 1 polymorphisms[J].Arch Med Res,2009,40(5):387-392.
-
6Marzena D,Hanna W,Pawel PJ.Impact of the sulfonylurea receptor 1(SUR1) exon 16-3c/t polymorphism on acute hyperglycaemia in type 2diabetic patients[J].Diabetes Res Clin Pract,2007,77(2):258-262.
-
7Zhang HJ,Liu XM,Kuang HY,et al.Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes[J].Diabetes Res Clin Praet,2007,77(1):58-61.
-
8de Morais SM,Schweikl H,Blaisdell J,et al.Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C《,18》[J].Biothem Biophys Res Commun,1993,194(1):194-201.
-
9Sullivan-Klose TH,Ghanayem BI,Bell DA,et al.The role of theCYP2C9-Leu359 allelic variant in the tolbutamide polymorphism[J].Pharmaeogenetics,1996,6(4):341-349.
-
10Miners JO,Birken DJ.Cytoehrome P4502C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol,1998,45(6):525-538.
-
1李经.纠正两个使用降糖药的误区[J].糖尿病之友,2013(1):64-64.
-
2徐晓红,葛秀丽.糖尿病口服降糖药物治疗[J].中国社区医师（医学专业）,2010,12(18):63-63.
-
3安良.口服降糖药详述[J].糖尿病新世界,2004(4):18-21. 被引量：1
-
4依貂.降糖“药”稳、准、对[J].糖尿病新世界,2012(10):28-29.
-
5服用降糖药最容易犯的八个错误[J].糖尿病天地（文摘刊）,2011(8):41-41.
-
6许樟荣.降糖药没有最好只有最适合[J].江苏卫生保健（今日保健）,2014(4):11-11.
-
7应对降糖药的不良反应[J].糖尿病天地（文摘刊）,2008(6):22-22.
-
8许樟荣.降糖药 没有最好只有最适合[J].医药与保健,2013(8):46-47.
-
9杨毅.如何正确使用口服降糖药[J].健康指南（中老年）,2014,0(8):46-48.
-
10杜汴兴,许庭郁,刘根源,许庭磊.药物基因组学与个体化给药[J].实用药物与临床,2007,10(6):367-368. 被引量：2
